Today: 12 November 2025
Subscribe
Browse Category

Investment Insights News 16 October 2025 - 29 October 2025

Vedanta’s Big Split Stumbles: Govt Roadblocks, Fresh Delays & What It Means for Investors

Vedanta’s Big Split Stumbles: Govt Roadblocks, Fresh Delays & What It Means for Investors

SEBI Greenlights Documents, But Final Approval Awaits Vedanta’s journey to split its diverse empire reached a tentative milestone when the Securities and Exchange Board of India (SEBI) approved the documentation for the demerger plan reuters.com. This essentially meant the market regulator did not object to the revised scheme on record, after earlier compliance checks. SEBI’s nod was crucial – the National Stock Exchange had already issued a no-objection certificate, and Vedanta’s shareholders and creditors had overwhelmingly approved the restructuring (with 99.99% of shareholders in favor, according to filings) in prior votes icicidirect.com icicidirect.com. However, SEBI’s clearance alone isn’t the finish line. The demerger
29 October 2025
 ·  ·  ·  · 
Celestica Stock Skyrockets on AI Boom: Q3 Blowout, Raised Forecasts Signal No Slowdown

Celestica (CLS) Stock Soars to Record High on AI Hardware Boom, Q3 Earnings Blowout

CLS Stock Rallies on AI Wave Celestica’s stock is on fire, extending an extraordinary run as investors bet on the AI hardware boom. On Tuesday, October 28, Celestica shares surged to record highs following its earnings news, reaching approximately C$462 in early trading (a ~9% jump) marketscreener.com. This added to a multi-session upswing – the stock gained about 13% in the past week alone ts2.tech – and marked a staggering ~316% increase from a year ago ts2.tech. Such a historic rally has vastly outpaced the broader market and reflects surging optimism that Celestica will be a big winner in the
28 October 2025
 ·  ·  ·  ·  · 
IonQ’s 2025 Quantum Leap: Surging Stock, Bold Ambitions & How It Compares to Rigetti and D-Wave

IonQ Stock’s Quantum Leap: Soaring 700% in a Year, $2 B Cash Boost & Bold Plans – Bubble or Breakthrough?

Stock Price & Intraday Movement (Oct 20, 2025) IonQ celebrated its public listing on the NYSE as a pure-play quantum computing company. IonQ’s stock seesawed on Monday amid continued volatility. After opening near $65, IONQ shares briefly spiked to about $65.50 before reversing and dipping as low as $58.80 intraday stockanalysis.com. By afternoon, the stock stabilized around $62.5, essentially flat (-0.6%) versus last week’s close stockanalysis.com. This breather comes on the heels of a breathtaking rally: on October 13, IonQ closed at $82.59, capping a single-day +16.9% jump ts2.tech ts2.tech. That peak marked roughly a +75% gain year-to-date and an astonishing ~700%
20 October 2025
 ·  ·  ·  ·  · 
What’s Driving American Water Works Stock Up ~4%? Key Facts and Insights

What’s Driving American Water Works Stock Up ~4%? Key Facts and Insights

In-depth analysis: American Water’s share rally comes amid broad market strength and positive utility news. CEO John Griffith highlighted the company’s momentum, saying AWK delivered “solid results for the first half of the year” and is “excited about the outlook for growth in the business” businesswire.com. The utility’s Q2 results support this: adjusted EPS of $1.48 beat last year’s $1.42, and revenues climbed 11.1% as new rate increases and recent acquisitions (like the Nexus Water Group deal adding ~87,000 customer connections) kicked in marketbeat.com businesswire.com. Importantly, management narrowed full-year 2025 EPS guidance to $5.70–$5.75 businesswire.com, reflecting confidence in robust second-half
20 October 2025
 ·  ·  ·  ·  · 
Lam Research Stock Soars on AI Chip Boom – What’s Next for LRCX?

Lam Research Stock Soars on AI Chip Boom – What’s Next for LRCX?

What to Know Before Markets Open on October 20, 2025 Lam Research’s Rally Fueled by AI and Earnings Beat Lam Research’s stock performance in late 2025 has been nothing short of remarkable. As of October 19, LRCX trades around $141.5 per share, a level it hasn’t seen in over a year (adjusted for its 10-for-1 stock split in late 2024) macrotrends.net. This price represents a nearly 40% gain since early August, when the stock was hovering near $100. The rally has dramatically outpaced broader indices – in the past month alone, Lam’s share price jumped almost 19%, while the Nasdaq
19 October 2025
 ·  ·  ·  ·  · 
Intel Stock Explodes: 10% U.S. Stake, Nvidia Deal & AI Hype Fuel Surge

Intel Stock Explodes: 10% U.S. Stake, Nvidia Deal & AI Hype Fuel Surge

Intel’s stock market roller-coaster has become one of 2025’s top stories. After languishing in the teens and low-$20s in early 2025, INTC shares have roared higher in recent months. By Oct. 17 the stock closed around $37, its highest since 2023 ts2.tech. As TS2.tech notes, the shares have “nearly doubled from its lows in January” on hopes of a turnaround ts2.tech. Much of the surge is tied to investor excitement over Intel’s role in the AI chip revolution and a flurry of unexpected big-money deals. One key catalyst was Washington’s intervention. In late August the Trump administration announced it would
19 October 2025
 ·  ·  ·  ·  · 
Chevron (CVX) Stock: Oil Price Doldrums, Pipeline Deal & Analysts’ Forecasts – What’s Next?

Chevron (CVX) Stock: Oil Price Doldrums, Pipeline Deal & Analysts’ Forecasts – What’s Next?

Current Stock Performance Chevron’s stock (NYSE: CVX) has been relatively flat in recent days. After closing around $152–153 last week investing.com, CVX closed at $153.08 on Oct 17 (up ~0.9% that day) investing.com. This puts it roughly in the middle of its 5-day range ($150–154) investing.com. Year-to-date CVX has lagged some competitors, reflecting weaker oil prices and the cost of merging Hess. For context, the broad S&P 500 is near all-time highs, while energy stocks are under pressure. Still, technical indicators (e.g. moving averages) suggest Chevron is holding important support in the mid-$140s. Recent Price Moves: Oil markets have swung
18 October 2025
 ·  ·  ·  ·  · 
Solana (SOL) Price Rollercoaster: From $250 Uptober High to $185 – Will It Rebound to $300?

Solana (SOL) Price Rollercoaster: From $250 Uptober High to $185 – Will It Rebound to $300?

Key Facts – October 18, 2025 SOL Price Struggles After Uptober Surge Solana’s price spiked above $250 in early October 2025 before a sharp pullback to the $180s. The chart shows SOL’s “Uptober” rollercoaster and key support levels around $170–$180. After a spectacular rally earlier this month, Solana (SOL) now trades around $185 as of October 18, 2025 investing.com. This week has been a rollercoaster: SOL fell below the $180 support on Friday, briefly dipping to two-month lows near $170 tradingview.com, before bouncing back modestly into the weekend. On Tuesday it had attempted to reclaim the $210 level but failed,
18 October 2025
 ·  ·  ·  · 
Costco Stock Surges Amid Retail Gloom – Will $900+ Shares Keep Climbing?

Costco (COST) Stock Slides to ~$924: Analyst Takeaways and Competitor Comparison (Oct 16, 2025)

Key Facts (Oct 16, 2025): – Costco shares traded around $924 today (Oct. 16), off roughly 3.4% from the prior close of $954.99 statmuse.com. – Fiscal Q4 2025 (ended Aug. 31) net sales were $84.4 billion (up 8.0% YoY) and net income $2.61 billion ($5.87 per share) investor.costco.com investor.costco.com, topping forecasts. – Same-store sales (excl. gas) rose 6.4%, slightly above analyst expectations reuters.com. – Membership fee revenue jumped 14% to $1.72 billion reuters.com. – Wall Street remains broadly bullish: consensus 12‑month price target ~$1,054 (≈18% above current) benzinga.com ts2.tech, with most analysts rating COST a “Buy.” – Peers on Oct. 16: Walmart ~105.7 USD (-2.6%) investing.com, Target ~89.1 USD (-1.4%) investing.com, BJ’s Wholesale ~94.2 USD (+0.1%) investing.com. – Economic backdrop: Deloitte projects sluggish holiday retail growth
16 October 2025
 ·  ·  ·  ·  · 
Battle of the EV Charging Standards: Tesla’s NACS vs. CCS2 vs. CHAdeMO – Who Will Rule the Roads in 2025?

Tesla Stock’s Wild Ride: Soars on Record Deliveries, Then Sags After Budget EV Reveal

Tesla’s mid-October stock action reflects this mix of good news and looming questions. On Oct 16, 2025, TSLA traded roughly flat in the mid-$430s (around $430 by mid-afternoon) reuters.com. That mild move belied a wildly volatile week. After hitting multi-month highs around $453 in early October, Tesla gave back ground on profit-taking. “Tesla’s stock has seesawed sharply,” noted our research: it surged ~5.4% on Oct 6, then plunged 4.5% on Oct 7, jumped again (+5.4%) on Oct 13, and slid ~1.5% on Oct 14 ts2.tech ts2.tech. Most recently, around Oct 10–14 the stock fell on a broad tech selloff and
16 October 2025
 ·  ·  ·  ·  · 
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX Stock Climbs on Arbli Launch Pills and a daily pill organizer: Arbli’s liquid formulation helps patients (especially children/elderly) who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market. In a GlobeNewswire press release that morning, Scienture announced that Arbli™ is now shipping through major pharmaceutical wholesalers nationwide globenewswire.com. Arbli is the first FDA-approved oral liquid form of losartan, a top-selling blood pressure drug. The launch news and accompanying marketing caused traders to bid up SCNX: one trader wrote that shares moved “from yesterday’s close around 72 cents to
16 October 2025
 ·  ·  ·  · 
Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma will be presented at the ESMO 2025 Congress on Oct. 20 ts2.tech. In this trial, patients receiving VCN-01 (an oncolytic adenovirus therapy) plus standard gemcitabine/nab-paclitaxel chemo showed markedly better outcomes than chemo alone. Interim data filed with the SEC reveal VCN-01 improved median overall survival to around 11–14 months versus ~8–11 months for chemo-only patients ts2.tech.
16 October 2025
 ·  ·  ·  · 
1 2 3 4 5 6 7
Go toTop